Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hans Tesch

Showing results (81-90 of 171) with videos related to

Pageof 18
Sort By:
Breast Care (Basel, Switzerland)|May 19, 2021
Challenges and Opportunities for Real-World Evidence in Metastatic Luminal Breast CancerDiana Lüftner, Andreas D Hartkopf, Michael P Lux, et al.
European Journal of Cancer (Oxford, England : 1990)|December 28, 2023
Efficacy, safety, and prognosis prediction in patients treated with ribociclib in combination with letrozole: Final results of phase 3b RIBECCA study in hormone receptor positive, human epidermal growth factor receptor-2 negative, locally advanced or metastatic breast cancerPeter A Fasching, Thomas Decker, Andreas Hartkopf, et al.
Geburtshilfe Und Frauenheilkunde|November 11, 2020
Update Breast Cancer 2020 Part 3 - Early Breast CancerJens Huober, Andreas Schneeweiss, Andreas D Hartkopf, et al.
Journal of the American Heart Association|November 16, 2020
Cardiotoxicity and Cardiovascular Biomarkers in Patients With Breast Cancer: Data From the GeparOcto-GBG 84 TrialAlexandra Maria Rüger, Andreas Schneeweiss, Sabine Seiler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2007
Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trialAndreas Engert, Jeremy Franklin, Hans Theodor Eich, et al.
Geburtshilfe Und Frauenheilkunde|December 27, 2019
Translational Highlights in Breast and Ovarian Cancer 2019 - Immunotherapy, DNA Repair, PI3K Inhibition and CDK4/6 TherapyAndreas D Hartkopf, Volkmar Müller, Achim Wöckel, et al.
Precision Clinical Medicine|January 22, 2025
Cell-free tumor DNA analysis in advanced or metastatic breast cancer patients: mutation frequencies, testing intention, and clinical impactHanna Huebner, Pauline Wimberger, Elena Laakmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 11, 2009
Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: a secondary analysis of the GeparTrio trial dataSerban Dan Costa, Sibylle Loibl, Manfred Kaufmann, et al.
Trials|May 17, 2023
PRECYCLE: multicenter, randomized phase IV intergroup trial to evaluate the impact of eHealth-based patient-reported outcome (PRO) assessment on quality of life in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated with palbociclib and an aromatase inhibitor or palbociclib and fulvestrantTom Degenhardt, Peter A Fasching, Diana Lüftner, et al.
Geburtshilfe Und Frauenheilkunde|December 1, 2018
Update Breast Cancer 2018 (Part 3) - Genomics, Individualized Medicine and Immune Therapies - in the Middle of a New Era: Prevention and Treatment Strategies for Early Breast CancerAchim Wöckel, Michael P Lux, Wolfgang Janni, et al.
Pageof 18

Showing results (81-90 of 171) with videos related to

Sort By:
Pageof 18
Breast Care (Basel, Switzerland)|May 19, 2021
Challenges and Opportunities for Real-World Evidence in Metastatic Luminal Breast CancerDiana Lüftner, Andreas D Hartkopf, Michael P Lux, et al.
European Journal of Cancer (Oxford, England : 1990)|December 28, 2023
Efficacy, safety, and prognosis prediction in patients treated with ribociclib in combination with letrozole: Final results of phase 3b RIBECCA study in hormone receptor positive, human epidermal growth factor receptor-2 negative, locally advanced or metastatic breast cancerPeter A Fasching, Thomas Decker, Andreas Hartkopf, et al.
Geburtshilfe Und Frauenheilkunde|November 11, 2020
Update Breast Cancer 2020 Part 3 - Early Breast CancerJens Huober, Andreas Schneeweiss, Andreas D Hartkopf, et al.
Journal of the American Heart Association|November 16, 2020
Cardiotoxicity and Cardiovascular Biomarkers in Patients With Breast Cancer: Data From the GeparOcto-GBG 84 TrialAlexandra Maria Rüger, Andreas Schneeweiss, Sabine Seiler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2007
Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trialAndreas Engert, Jeremy Franklin, Hans Theodor Eich, et al.
Geburtshilfe Und Frauenheilkunde|December 27, 2019
Translational Highlights in Breast and Ovarian Cancer 2019 - Immunotherapy, DNA Repair, PI3K Inhibition and CDK4/6 TherapyAndreas D Hartkopf, Volkmar Müller, Achim Wöckel, et al.
Precision Clinical Medicine|January 22, 2025
Cell-free tumor DNA analysis in advanced or metastatic breast cancer patients: mutation frequencies, testing intention, and clinical impactHanna Huebner, Pauline Wimberger, Elena Laakmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 11, 2009
Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: a secondary analysis of the GeparTrio trial dataSerban Dan Costa, Sibylle Loibl, Manfred Kaufmann, et al.
Trials|May 17, 2023
PRECYCLE: multicenter, randomized phase IV intergroup trial to evaluate the impact of eHealth-based patient-reported outcome (PRO) assessment on quality of life in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated with palbociclib and an aromatase inhibitor or palbociclib and fulvestrantTom Degenhardt, Peter A Fasching, Diana Lüftner, et al.
Geburtshilfe Und Frauenheilkunde|December 1, 2018
Update Breast Cancer 2018 (Part 3) - Genomics, Individualized Medicine and Immune Therapies - in the Middle of a New Era: Prevention and Treatment Strategies for Early Breast CancerAchim Wöckel, Michael P Lux, Wolfgang Janni, et al.
Pageof 18